JP2022533215A5 - - Google Patents

Info

Publication number
JP2022533215A5
JP2022533215A5 JP2021568944A JP2021568944A JP2022533215A5 JP 2022533215 A5 JP2022533215 A5 JP 2022533215A5 JP 2021568944 A JP2021568944 A JP 2021568944A JP 2021568944 A JP2021568944 A JP 2021568944A JP 2022533215 A5 JP2022533215 A5 JP 2022533215A5
Authority
JP
Japan
Prior art keywords
indicates
bond
nhc
independently selected
spacer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021568944A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533215A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/033648 external-priority patent/WO2020236841A2/en
Publication of JP2022533215A publication Critical patent/JP2022533215A/ja
Publication of JP2022533215A5 publication Critical patent/JP2022533215A5/ja
Priority to JP2025144373A priority Critical patent/JP2026000940A/ja
Pending legal-status Critical Current

Links

JP2021568944A 2019-05-20 2020-05-19 親水性基を含むリンカーを有する抗体薬剤コンジュゲート Pending JP2022533215A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025144373A JP2026000940A (ja) 2019-05-20 2025-09-01 親水性基を含むリンカーを有する抗体薬剤コンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962850094P 2019-05-20 2019-05-20
US62/850,094 2019-05-20
PCT/US2020/033648 WO2020236841A2 (en) 2019-05-20 2020-05-19 Antibody drug conjugates having linkers comprising hydrophilic groups

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025144373A Division JP2026000940A (ja) 2019-05-20 2025-09-01 親水性基を含むリンカーを有する抗体薬剤コンジュゲート

Publications (2)

Publication Number Publication Date
JP2022533215A JP2022533215A (ja) 2022-07-21
JP2022533215A5 true JP2022533215A5 (https=) 2023-05-26

Family

ID=71070004

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568944A Pending JP2022533215A (ja) 2019-05-20 2020-05-19 親水性基を含むリンカーを有する抗体薬剤コンジュゲート
JP2025144373A Pending JP2026000940A (ja) 2019-05-20 2025-09-01 親水性基を含むリンカーを有する抗体薬剤コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025144373A Pending JP2026000940A (ja) 2019-05-20 2025-09-01 親水性基を含むリンカーを有する抗体薬剤コンジュゲート

Country Status (9)

Country Link
US (1) US20230091510A1 (https=)
EP (1) EP3972650A2 (https=)
JP (2) JP2022533215A (https=)
KR (1) KR20220010527A (https=)
CN (3) CN113853219B (https=)
AU (2) AU2020279731B2 (https=)
CA (1) CA3140063A1 (https=)
IL (1) IL287596A (https=)
WO (1) WO2020236841A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202308700A (zh) * 2021-04-29 2023-03-01 大陸商上海匯連生物醫藥有限公司 抗體偶聯藥物的製備方法及應用
AU2022286137A1 (en) 2021-06-01 2023-12-14 Ajinomoto Co., Inc. Conjugate of antibody and functional substance or salt of said conjugate, and compound for use in production of said conjugate or salt of said compound
CN117295524A (zh) * 2021-06-02 2023-12-26 百奥泰生物制药股份有限公司 药物偶联物及其用途
WO2022262516A1 (zh) * 2021-06-18 2022-12-22 北京海步医药科技有限公司 连接子及其缀合物
EP4509141A1 (en) * 2022-04-12 2025-02-19 Bio-Thera Solutions, Ltd. Method for treating her2-positive solid tumor
US20260061065A1 (en) * 2022-05-20 2026-03-05 Novartis Ag Antibody drug conjugates
WO2024083162A1 (en) * 2022-10-19 2024-04-25 Multitude Therapeutics Inc. Antibodies, antibody-drug conjugates, preparations and uses thereof
CN116036303B (zh) * 2023-01-10 2025-06-24 金麦安博生物制药(苏州)有限公司 一种抗体-药物偶联物及其制备方法和应用
WO2024149345A1 (en) * 2023-01-11 2024-07-18 Profoundbio Us Co. Linkers, drug linkers and conjugates thereof and methods of using the same
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof
WO2025228305A1 (zh) * 2024-04-28 2025-11-06 中国科学院上海药物研究所 一种蛋白降解剂缀合物及其偶联物
KR20250164033A (ko) * 2024-05-14 2025-11-24 주식회사 지놈앤컴퍼니 항-bcam 항체 및 이의 컨쥬게이트
WO2025255381A1 (en) * 2024-06-05 2025-12-11 Sigma-Aldrich Co. Llc Chito-oligosaccharide drug constructs
WO2026046186A1 (en) * 2024-08-27 2026-03-05 Suzhou Bioreinno Biotechnology Limited Company Linkers, linker conjugates and conjugate compounds thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
ES2732574T3 (es) 2012-11-30 2019-11-25 Novartis Ag Métodos para preparar conjugados a partir de proteínas que contienen disulfuro
US9089614B2 (en) * 2012-12-21 2015-07-28 Bioalliance C.V. Hydrophilic self-immolative linkers and conjugates thereof
EP2953976B1 (en) 2013-02-08 2021-03-24 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
NZ758049A (en) * 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
US10550190B2 (en) * 2014-04-04 2020-02-04 Merck Sharp & Dohme Corp. Phosphate based linkers for intracellular delivery of drug conjugates
US9950077B2 (en) * 2014-06-20 2018-04-24 Bioalliance C.V. Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
SG11201610624WA (en) * 2014-06-20 2017-01-27 Bioalliance Cv Anti-cd22 antibody-drug conjugates and methods of using thereof
CN111620861A (zh) * 2014-12-09 2020-09-04 艾伯维公司 具有低细胞渗透性的bcl-xl抑制性化合物以及包括它的抗体药物缀合物
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
RU2018147224A (ru) * 2016-06-08 2020-07-14 Эббви Инк. Конъюгаты антитела к egfr и лекарственного средства
CN108066772B (zh) 2016-11-14 2021-07-13 中国科学院上海药物研究所 靶向tacstd2的抗体与药物偶联体(adc)分子
US11135307B2 (en) * 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
US10646585B2 (en) * 2017-09-15 2020-05-12 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and ligand-drug conjugates thereof
JP7381478B2 (ja) * 2017-10-23 2023-11-15 マブリンク ビオシオンス 単一分子量ポリサルコシンを含むリガンド－薬物－複合体
MX2020004691A (es) * 2017-11-07 2020-08-20 Regeneron Pharma Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.

Similar Documents

Publication Publication Date Title
JP2022533215A5 (https=)
CN1056162C (zh) 聚胺化的配位体及其金属配合物
JP2023512455A5 (https=)
JP2022507781A5 (https=)
JP2023113639A (ja) ビス－オクタヒドロフェナントレンカルボキサミド及びそのタンパク質コンジュゲート
US20100160485A1 (en) Hydrolysis stable self-etching, self-priming adhesive
JP2024524613A5 (https=)
JP2022512643A5 (https=)
AU2004201789A1 (en) Fc receptor modulators and uses thereof
RU98120057A (ru) Производные d-пролина
JP6051223B2 (ja) ペプチドの放出可能な結合のためのチロシンに基づくリンカー
CA2217550A1 (en) Cationic lipids for gene therapy
WO2006088248A1 (ja) ポリオキシアルキレン誘導体
JP2003506491A5 (https=)
CN101240030B (zh) 正十一烷基和rgd肽构建的缀合物、它们的合成及在医学中的应用
FI78300B (fi) Foerfarande foer framstaellning av farmakologiskt verkande fosfatidylfoereningar.
JP2022512401A5 (https=)
US9586916B2 (en) Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3
JP2024509282A5 (https=)
JP2019507126A5 (https=)
JP2024542021A5 (https=)
RU2004121776A (ru) Производные тетрагидрокарбазола, способ получения производных тетрагидрокарбазола (варианты), их применение (варианты) и фармацевтическая композиция, обладающая активностью антагониста гонадотропин-рилизинг-гормона (варианты)
WO1995026360A1 (en) Antagonists of endothelin receptors
JP3274225B2 (ja) アミノ酸誘導体及びその用途
JP4226324B2 (ja) カルボン酸型脂質